Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Article Dans Anglais | IMSEAR | ID: sea-39455

Résumé

OBJECTIVE: To compare the efficacy of combined low dose of hypouricemic drugs (Allopurinol 100 mg and benzbromarone 20 mg; Allomaron) and standard dose 300 mg of allopurinol in hyperuricemia. MATERIAL AND METHOD: A prospective, open study of 94 hyperuricemic patients was done at King Chulalongkorn Memorial Hospital. Each group of 47 patients was given a combined low dose of hypouricemic drugs (Allopurinol 100 mg and benzbromarone 20 mg; Allomaron) and a standard dose 300 mg of allopurinol. Serum uric acid was measured before and 4 weeks after receiving the drugs. The efficacy was measured from the difference of the level of serum uric acid before and after receiving the drugs. RESULTS: The patients receiving the combined low dose of hypouricemic drugs and standard dose of allopurinol showed a mean reduction of serum uric acid of 2.5+/-3.4 mg/dl and 4.1+/-2.7 mg/dl consecutively. There was a statistically significant difference between the 2 groups (P = 0.010). CONCLUSION: This study demonstrates that the efficacy of standard dose 300 mg of allopurinol is superior to a combined low dose of allopurinol and benzbromarone in lowering the level of serum uric acid level.


Sujets)
Allopurinol/administration et posologie , Benzbromarone/administration et posologie , Relation dose-effet des médicaments , Calendrier d'administration des médicaments , Association de médicaments , Femelle , Goutte/sang , Antigoutteux/administration et posologie , Humains , Mâle , Adulte d'âge moyen , Études prospectives , Résultat thérapeutique , Acide urique/sang , Uricosuriques/administration et posologie
2.
Article Dans Anglais | IMSEAR | ID: sea-45518

Résumé

This study was aimed to evaluate the efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients with normal renal function (serum creatinine < or = 1.5). The authors conducted a crossover study consisting of two four-week treatment periods of allopurinol 300 mg/day and benzbromarone 100 mg/day separated by a four-week washout period. Fourteen patients with mean age and duration of hyperuricemia of 60.78 +/- 8.62 and 6.93 +/- 3.69 years, respectively, were recruited and all completed our study protocol. This study was a crossover design consisting of two four-week treatments of allopurinol and benzbromarone separated by a four-week washout period. The serum uric acid level was reduced from 9.89 +/- 1.43 mg/dl to 5.52 +/- 0.83 mg/dl and from 9.53 +/- 1.48 to 4.05 +/- 0.87 mg/dl by allopurinol and benzbromarone, respectively. The efficacy of benzbromarone in lowering serum uric acid level was significantly superior to allopurinol (p=0.005). No patient reported clinical side effects during treatment with either drug. In conclusion, the authors have shown that benzbromarone is more effective than allopurinol in the reduction of serum uric acid levels in hyperuricemic patients with normal renal function.


Sujets)
Adulte , Sujet âgé , Allopurinol/administration et posologie , Benzbromarone/administration et posologie , Études croisées , Relation dose-effet des médicaments , Calendrier d'administration des médicaments , Femelle , Études de suivi , Goutte/sang , Humains , Mâle , Adulte d'âge moyen , Probabilité , Statistique non paramétrique , Résultat thérapeutique , Acide urique/sang , Uricosuriques/administration et posologie , Examen des urines
SÉLECTION CITATIONS
Détails de la recherche